ACTIVE

Lakefront Biotherapeutics

Export PDF

Financial year 2025 · closed on 31/12/2025

Net result

316,9 M €

+563.3% YoY

Revenue

1,1 Md €

+263.4% YoY

Equity

3,1 Md €

+11.2% YoY

Workforce

172,9 ETP

-40.7% YoY

What does Lakefront Biotherapeutics do?

Lakefront Biotherapeutics is a Public limited company incorporated in 1999. Its registered office is in Mechelen. It employs on average 172,9 ETP workers (FTE).

Legal situation

● Normal situation

BCE/KBO no. / VAT

BE 0466.460.429

Incorporation

06/07/1999

Legal form

Public limited company

Registered office

Schaliënhoevedreef 20T
2800 Mechelen · FlandreSee on map

Contributed capital

3 017 626 375,00 €

Latest accounts

31/12/2025

Average workforce

172,9 ETP

Joint committees (1)

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHigh revenue

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 15 financial years

	2025		2024		2023		2022		2021		2020		2019		2018		2017		2016		2015		2014		2013		2012		2009
Income statement
Revenue	1,1 Md €	+263%	303,4 M €	-51.8%	628,9 M €	+50.3%	418,5 M €	-16.9%	503,4 M €	-9.9%	558,8 M €	-38.1%	902,8 M €	+312%	219 M €	+66.5%	131,5 M €	-18.8%	162 M €	+171%	59,9 M €	-5.0%	63 M €	+30.4%	48,3 M €	+5.1%	46 M €	-11.5%	51,9 M €
EBITDA	735,5 M €	+718%	89,9 M €	-79.3%	433,7 M €	+239%	127,8 M €	-38.5%	207,8 M €	-42.1%	358,9 M €	-55.0%	797,2 M €	+385%	164,3 M €	+47.1%	111,7 M €	-26.2%	151,4 M €	+361%	32,8 M €	-36.9%	51,9 M €	+1.7%	51,1 M €	+12.3%	45,5 M €	+839%	-6,2 M €
Operating result	390,2 M €	+288%	-207,7 M €	-401%	69 M €	+130%	-231,7 M €	-20.9%	-191,7 M €	-75.9%	-108,9 M €	-128%	393,9 M €	+378%	-141,4 M €	-1.2%	-139,8 M €	-168%	-52,2 M €	-4.8%	-49,8 M €	-100.0%	-24,9 M €	-58.2%	-15,7 M €	-133041%	-11,8 k €	+99.8%	-7,5 M €
Net result	316,9 M €	+563%	47,8 M €	-82.4%	271,3 M €	+297%	-138 M €	-48.8%	-92,7 M €	+52.7%	-196 M €	-152%	379 M €	+428%	-115,7 M €	+30.3%	-165,9 M €	-267%	-45,2 M €	+28.2%	-63 M €	-202%	62 M €	+477%	-16,4 M €	+39.7%	-27,2 M €	-268%	-7,4 M €
Balance sheet
Equity	3,1 Md €	+11.2%	2,8 Md €	+1.7%	2,8 Md €	+10.9%	2,5 Md €	-5.0%	2,6 Md €	-3.3%	2,7 Md €	-5.8%	2,9 Md €	+147%	1,2 Md €	+19.1%	985 M €	+25.8%	783,3 M €	+80.2%	434,8 M €	+110%	207,3 M €	+47.2%	140,8 M €	+42.8%	98,6 M €	-9.0%	108,4 M €
Total assets	3,3 Md €	-17.4%	4 Md €	-6.0%	4,3 Md €	-8.4%	4,7 Md €	-8.3%	5,1 Md €	-8.6%	5,6 Md €	-6.7%	6 Md €	+321%	1,4 Md €	+10.8%	1,3 Md €	+12.9%	1,1 Md €	+101%	568,5 M €	+46.5%	388 M €	+6.0%	366,1 M €	+23.5%	296,5 M €	+109%	141,8 M €
Cash	82,3 M €	+36.8%	60,1 M €	-13.3%	69,4 M €	-84.8%	455,1 M €	-62.2%	1,2 Md €	+0.3%	1,2 Md €	+35.4%	886,8 M €	+72.9%	512,8 M €	+19.7%	428,3 M €	-18.7%	526,7 M €	+55.2%	339,4 M €	+137%	143 M €	+15.5%	123,8 M €	+73.6%	71,3 M €	+126%	31,6 M €
Debts	126,7 M €	-8.6%	138,7 M €	-31.3%	201,9 M €	-32.8%	300,2 M €	+24.0%	242,1 M €	+5.0%	230,6 M €	-5.0%	242,7 M €	+68.1%	144,4 M €	+41.9%	101,7 M €	+29.7%	78,4 M €	+27.8%	61,4 M €	+8.9%	56,4 M €	+4.5%	53,9 M €	+9.6%	49,2 M €	+116%	22,7 M €
Other
Workforce	172,9 ETP	-40.7%	291,5 ETP	-20.9%	368,6 ETP	-14.8%	432,6 ETP	-11.1%	486,5 ETP	+11.5%	436,3 ETP	+41.5%	308,4 ETP	+30.6%	236,2 ETP	+33.5%	176,9 ETP	+31.6%	134,4 ETP	+8.6%	123,8 ETP	-5.0%	130,3 ETP	+15.2%	113,1 ETP	+4.5%	108,2 ETP	+9.1%	99,2 ETP

Estimate

Indicative valuation

As an indication, this company is worth

more than 1.000 M€

See the valuation

Governance

Board of directors

Seen on filing of 31/12/2024 · 9 active · 56 ended

Active mandates

Oleg Nodelman

Director · since 07 octobre 2024 · until 28 avril 2026

Active

Elisabeth Svanberg

Director · since 30 avril 2024 · until 25 avril 2028

Active

Andrew Dickinson

Director · since 27 mars 2024 · until 30 avril 2028

Active

Simon Sturge

Director · since 19 septembre 2023 · until 25 avril 2028

Active

Susanne Schaffert

Director · since 12 juin 2023 · until 25 avril 2028

Active

Linda Higgins

Director · since 25 avril 2023 · until 27 avril 2027

Active

Peter Guenter

Director · since 25 avril 2023 · until 27 avril 2027

Active

Jérôme Contamine

Director · since 26 avril 2022 · until 28 avril 2026

Active

Stoffels IMC

Chairman of the board of directors · since 26 avril 2022 · until 28 avril 2026 · 0780.918.294

Represented by Paul Stoffels

Active

Ended mandates

Simon Sturge

Director · since 19 septembre 2023 · until 30 avril 2028

Ended

Susanne Schaffert

Director · since 12 juin 2023 · until 30 avril 2028

Ended

Daniel O'Day

Director · since 25 avril 2023 · until 27 avril 2027

Ended

Dan Baker

Director · since 26 avril 2022 · until 28 avril 2026

Ended

At this address

Other companies at this address

Company	CBE no.
ADAM SOLUTIONS● Active	0775.695.538
AEW Van Gestel● Active	0849.883.316
AGY CONSTRUCT● Bankrupt	0790.907.019
Alfasigma Belgium● Active	0816.612.415
Allego België● Active	0541.674.724
ASTERION BELGIUM● Active	0475.120.747
Axxerion Belgium● Active	0688.696.436
Bizantium Ventures● Active	1002.497.770
BLUESUN CONSUMER BRANDS● Active	0685.794.849
Brabamij Infra● Active	0831.923.864
CDA Mobilitycare● Active	1031.475.333
Checkpoint Systems Belgium● Active	0736.877.623
COMFORTDRIVE.SERVICES● Bankrupt	0668.972.475
CONTINIA SOFTWARE BELGIUM● Active	0744.984.645
Curium Belgium● Active	0500.920.272
Dorabella● Active	1023.691.874
ERIS● Active	0879.568.284
Eurofins Professional Scientific Services Belgium● Active	0553.909.095
EVMora● Active	1038.961.951
FINAL TOUCH● Active	0461.367.236

Annual accounts

Full financial information

	2025	2024	2023	2022	2021	2020
Type of account	Full model	Full model	Full model	Full model	Full model	m120-f-p
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	05/06/2026	22/05/2025	20/06/2024	12/05/2023	29/04/2022	27/05/2021
General meeting	28/04/2026	29/04/2025	30/04/2024	25/04/2023	26/04/2022	28/04/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

40 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2025	28/04/2026	05/06/2026	Dutch	PDF
m120-f-p	31/12/2025	28/04/2026	29/05/2026	Dutch	PDF
Full model	31/12/2024	29/04/2025	22/05/2025	Dutch	PDF
m120-f-p	31/12/2024	29/04/2025	22/05/2025	Dutch	PDF
Full model	31/12/2023	30/04/2024	20/06/2024	Dutch	PDF
m120-f-p	31/12/2023	30/04/2024	22/08/2024	Dutch	PDF
Full model	31/12/2022	25/04/2023	12/05/2023	Dutch	PDF
m120-f-p	31/12/2022	25/04/2023	11/05/2023	Dutch	PDF
Full model	31/12/2021	26/04/2022	29/04/2022	Dutch	PDF
m120-f-p	31/12/2021	26/04/2022	29/04/2022	Dutch	PDF
Full model	31/12/2020	28/04/2021	26/05/2021	Dutch	PDF
m120-f-p	31/12/2020	28/04/2021	27/05/2021	Dutch	PDF
Full model	31/12/2019	28/04/2020	28/05/2020	Dutch	PDF
m120-f-p	31/12/2019	28/04/2020	28/05/2020	Dutch	PDF
Full model	31/12/2018	30/04/2019	19/06/2019	Dutch	PDF
m120-f-p	31/12/2018	30/04/2019	19/06/2019	Dutch	PDF
Full model	31/12/2017	24/04/2018	14/06/2018	Dutch	PDF
m120-f-p	31/12/2017	24/04/2018	14/06/2018	Dutch	PDF
Full model	31/12/2016	25/04/2017	20/06/2017	Dutch	PDF
m120-f-p	31/12/2016	25/04/2017	20/06/2017	Dutch	PDF
Full model	31/12/2015	26/04/2016	14/06/2016	Dutch	PDF
m120-f-p	31/12/2015	26/04/2016	15/06/2016	Dutch	PDF
Full model	31/12/2014	28/04/2015	22/06/2015	Dutch	PDF
m120-f-p	31/12/2014	28/04/2015	22/06/2015	Dutch	PDF

View all 40 filings

Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

more than 1.000 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2024 · 9 active · 56 ended

Active mandates

Oleg Nodelman

Director · since 07 octobre 2024 · until 28 avril 2026

Active

Elisabeth Svanberg

Director · since 30 avril 2024 · until 25 avril 2028

Active

Andrew Dickinson

Director · since 27 mars 2024 · until 30 avril 2028

Active

Simon Sturge

Director · since 19 septembre 2023 · until 25 avril 2028

Active

Susanne Schaffert

Director · since 12 juin 2023 · until 25 avril 2028

Active

Linda Higgins

Director · since 25 avril 2023 · until 27 avril 2027

Active

Peter Guenter

Director · since 25 avril 2023 · until 27 avril 2027

Active

Jérôme Contamine

Director · since 26 avril 2022 · until 28 avril 2026

Active

Stoffels IMC

Chairman of the board of directors · since 26 avril 2022 · until 28 avril 2026 · 0780.918.294

Represented by Paul Stoffels

Active

Ended mandates

Simon Sturge

Director · since 19 septembre 2023 · until 30 avril 2028

Ended

Susanne Schaffert

Director · since 12 juin 2023 · until 30 avril 2028

Ended

Daniel O'Day

Director · since 25 avril 2023 · until 27 avril 2027

Ended

Dan Baker

Director · since 26 avril 2022 · until 28 avril 2026

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Other11/09/2026
DIVERSEN
PDF
Other02/07/2026
DIVERSEN
PDF
Mandates01/06/2026
ONTSLAGEN - BENOEMINGEN
PDF
Other27/05/2026
DIVERSEN
PDF
Other12/05/2026
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - BENAMING
PDF
Registered office12/05/2026
MAATSCHAPPELIJKE ZETEL
PDF
Other31/03/2026
DIVERSEN
PDF
Mandates30/03/2026
ONTSLAGEN - BENOEMINGEN
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

28/04/2026
nominationGino Santini — niet-uitvoerend lid van de Raad van Bestuur
09/02/2026
nominationPaulo Fontoura — onafhankelijk niet-uitvoerend lid van de Raad van Bestuur
09/02/2026
nominationPaulo Fontoura — niet-uitvoerende onafhankelijke bestuurder
2025
Annual accounts 2025316,9 M €↑
01/11/2025
nominationNeil Johnston — onafhankelijk niet-uitvoerend lid van de Raad van Bestuur
01/11/2025
nominationDevang Bhuva — niet-uitvoerend lid van de Raad van Bestuur
01/11/2025
nominationDr. Neil Johnston — niet-uitvoerende onafhankelijke bestuurder
01/11/2025
nominationDevang Bhuva — niet-uitvoerende niet-onafhankelijke bestuurder
16/10/2025
nominationFred Blakeslee — General Counsel en lid van het Directiecomité
01/10/2025
apport
28/07/2025
nominationJane Griffiths — onafhankelijk niet-uitvoerend lid van de Raad van Bestuur
28/07/2025
nominationDawn Svoronos — onafhankelijk niet-uitvoerend lid van de Raad van Bestuur
28/07/2025
nominationDawn Svoronos — niet-uitvoerende onafhankelijke bestuurder
28/07/2025
nominationJane Griffiths — niet-uitvoerende onafhankelijke bestuurder
07/07/2025
nominationAaron Cox — Chief Financial Officer en lid van het Directiecomité
12/05/2025
nominationHenry Gosebruch — uitvoerend lid van de Raad van Bestuur
12/05/2025
nominationHenry Gosebruch — uitvoerend bestuurder
2025
Name changeLakefront Biotherapeutics
2024
Annual accounts 202447,8 M €↓
07/10/2024
nominationOleg Nodelman — niet-uitvoerend bestuurder
07/10/2024
nominationOleg Nodelman — niet-uitvoerende en niet-onafhankelijke Bestuurder
30/04/2024
reconductionElisabeth Svanberg — onafhankelijk niet-uitvoerend lid van de Raad van Bestuur
30/04/2024
nominationSusanne Schaffert — onafhankelijk niet-uitvoerend lid van de Raad van Bestuur
30/04/2024
nominationSimon Sturge — onafhankelijk niet-uitvoerend lid van de Raad van Bestuur
27/03/2024
nominationAndrew Dickinson — niet-uitvoerende Bestuurder
01/01/2024
nominationPaul Stoffels — Chief Executive Officer
01/01/2024
nominationThad Hudson — Chief Operating Officer en Chief Financial Officer
01/01/2024
nominationAnnelies Missotten — Chief Human Resources Officer
01/01/2024
nominationValeria Cnossen — General Counsel
2023
Annual accounts 2023271,3 M €↑
19/09/2023
nominationPaul Stoffels — Voorzitter van de Raad van Bestuur
19/09/2023
nominationLinda Higgins — bestuurder
19/09/2023
nominationDaniel O'Day — bestuurder
19/09/2023
nominationDan G. Baker — onafhankelijk bestuurder
19/09/2023
nominationJérôme Contamine — onafhankelijk bestuurder
19/09/2023
nominationPeter Guenter — onafhankelijk bestuurder
19/09/2023
nominationElisabeth Svanberg — onafhankelijk bestuurder
19/09/2023
nominationSusanne Schaffert — onafhankelijk bestuurder
19/09/2023
nominationSimon Sturge — onafhankelijk bestuurder
19/09/2023
nominationSimon Sturge — niet-uitvoerende onafhankelijke Bestuurder
01/07/2023
nominationThad Huston — Chief Operating Officer en Chief Financial Officer
12/06/2023
nominationDr. Susanne Schaffert — niet-uitvoerende onafhankelijke Bestuurder
25/04/2023
nominationBDO Bedrijfsrevisoren BV — commissaris
25/04/2023
reconductionPeter Guenter — onafhankelijk lid van de Raad van Bestuur
25/04/2023
reconductionDaniel O'Day — niet-onafhankelijk lid van de Raad van Bestuur
25/04/2023
reconductionDr. Linda Higgins — niet-onafhankelijk lid van de Raad van Bestuur
20/03/2023
augmentation_capital
01/01/2023
nominationAnnelies Missotten — lid van het Directiecomité als Chief Human Resources Officer
01/01/2023
nominationValeria Cnossen — lid van het Directiecomité als General Counsel
2022
Annual accounts 2022-138 M €↓
27/09/2022
augmentation_capital
20/06/2022
augmentation_capital
26/04/2022
nominationBart Filius — President, COO & CFO
26/04/2022
nominationAndreas Hoekema — CBO
26/04/2022
nominationWalid Abi-Saab — CMO
26/04/2022
nominationMichele Manto — CCO
01/04/2022
nominationStoffels IMC BV — CEO
26/01/2022
nominationStoffels IMC BV — lid van de directieraad
2021
Annual accounts 2021-92,7 M €↑
2020
Annual accounts 2020-196 M €↓
2019
Annual accounts 2019379 M €↑
2018
Annual accounts 2018-115,7 M €↑
2017
Annual accounts 2017-165,9 M €↓
2016
Annual accounts 2016-45,2 M €↑
2015
Annual accounts 2015-63 M €↓
2014
Annual accounts 201462 M €↑
2013
Annual accounts 2013-16,4 M €↑
2012
Annual accounts 2012-27,2 M €↓
2009
Annual accounts 2009-7,4 M €
2009
Name changeGalapagos
06/07/1999
IncorporationPublic limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

Lakefront Biotherapeutics

Overview

What does Lakefront Biotherapeutics do?

Trend over 15 financial years

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline